Quantcast
Last updated on April 18, 2014 at 5:21 EDT

Latest Abiraterone Stories

2012-10-01 02:31:07

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, announced new data from an ongoing, open-label, multicenter Phase II study of ARN-509, the company's 2nd generation androgen receptor antagonist, demonstrating promising results of ARN-509 in three separate patient populations with castration resistant prostate cancer (CRPC). Data were presented at the European Society for Medical Oncology 2012 Annual Meeting in...

2012-09-30 02:20:13

VIENNA, Sept. 30, 2012 /PRNewswire/ -- Additional data from pre-specified interim analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study, suggested ZYTIGA(®) (abiraterone acetate) plus prednisone, compared to placebo plus prednisone, delayed pain progression and functional decline in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients whose disease progressed after androgen deprivation therapy and anti-androgens. Additional...

2012-09-27 10:26:12

BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 27, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed. The trial will investigate if combining custirsen with docetaxel, a standard second-line NSCLC chemotherapy, has the potential to...

2012-09-05 02:32:26

SEATTLE, Sept. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga®) and prednisone. PX-866 is Oncothyreon's small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K),...

2012-08-29 02:25:31

RARITAN, N.J., Aug. 29, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA(®) (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy....

2012-06-04 02:25:49

Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA® Plus Prednisone TORONTO, June 2, 2012 /CNW/ - New data presented this weekend at the 48(th) annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA® (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy....

2012-06-01 18:20:41

CHICAGO, June 2, 2012 /PRNewswire/ -- Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA(®)) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus...

2012-05-25 02:21:30

NEW BRUNSWICK, N.J., May 25, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, June 2 at approximately 10:00 a.m., Eastern Time, to coincide with the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Ill. Results from pre-specified interim analyses of COU-AA-302, a randomized, phase 3 study of abiraterone acetate in chemotherapy-naive patients with metastatic...

2012-05-18 02:24:27

RARITAN, N.J., May 18, 2012 /PRNewswire/ -- Data related to ZYTIGA® (abiraterone acetate) clinical studies have been selected for presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). Additionally, data regarding the investigational compounds ibrutinib and siltuximab also have been accepted for presentation. Additional abstracts were also accepted as publication-only or in the trial in progress category. These studies were sponsored by...

2012-05-03 10:26:21

Conference call to be held on Thursday, May 3, 2012 at 4:30 p.m. Eastern Time BOTHELL, WA, and VANCOUVER, May 3, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced first quarter 2012 financial results and provided an overview of the clinical development activities of its two product candidates, custirsen and OGX-427. Custirsen Clinical Development Highlights -- In the first quarter, OncoGenex and development partner, Teva...